Sleep issues in Parkinson's disease

Neurology

Volumn 64, Issue 12 SUPPL. 3, 2005, Pages

  Adler, Charles H ^a   Thorpy, Michael J ^b  

^a MAYO CLINIC   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; CAFFEINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLOZAPINE; DESMOPRESSIN; DEXAMPHETAMINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; GABAPENTIN; GALANTAMINE; HYPNOTIC AGENT; LEVODOPA; MELATONIN; MODAFINIL; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; OPIATE; OXYBUTYNIN; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TERAZOSIN; TOLTERODINE; TRAZODONE; ZALEPLON; ZOLPIDEM;

ACUPUNCTURE; AGITATION; AKINESIA; ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; BLOOD DYSCRASIA; BRADYKINESIA; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEMENTIA; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FATIGUE; FOOT PAIN; HALLUCINATION; HUMAN; INSOMNIA; LIGHT EXPOSURE; LOW DRUG DOSE; MOTOR DYSFUNCTION; NARCOLEPSY; NERVOUSNESS; NEUROPROTECTION; NIGHT SLEEP; NIGHTMARE; NOCTURIA; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PARKINSONISM; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSYCHOSIS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP PATTERN; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; SOMNOLENCE; URINARY DYSFUNCTION; URINE RETENTION; VIVID DREAM;

EID: 21044442252     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.64.12_suppl_3.s12     Document Type: Review

References (109)

1. Williams RL, Karacan I, Hursch CJ. Electroencephalography (EEG) of human sleep: clinical applications. New York: John Wiley & Sons, 1974.
2. Gooneratne NS, Weaver TE, Cater JR, et al. Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc 2003; 51:642-649.
3. Ancoli-Israel S. Epidemiology of sleep disorders. Clin Geriatr Med 1989;5:347-362.
4. Carskadon MA, van den Hoed J, Dement WC. Sleep and daytime sleepiness in the elderly. J Geriatr Psychiatry 1980;13:135-151.
5. Happe S, Schrödl B, Faltl M, Müller C, Auff E, Zeitlhofer J. Sleep disorders and depression in patients with Parkinson's disease: results of a study with the Sleep Disorders Questionnaire (SDQ) and the Zung Depression Scale (ZDS). Acta Neurol Scand 2001;104:275-280.
6. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13: 895-899.
7. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord 2002;17:775-781.
8. Wetter TC, Collado-Seidel V, Pollmacher T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 2000;23:361-367.
9. Young A, Home M, Churchward T, Freezer N, Holmes P, Ho M. Comparison of sleep disturbance in mild versus severe Parkinson's disease. Sleep 2002;25:573-577.
10. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000;41:167-184.
11. Wetter TC, Trenkwalder C, Gershanik O, Hogl B. Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. Wien Klin Wochenschr 2001; 113:249-253.
12. Ancoli-Israel S, Kripke DF, Klauber MR, et al. Morbidity, mortality and sleep-disordered breathing in community dwelling elderly. Sleep 1996;19:277-282.
13. Ferini-Strambi L, Franceschi M, Pinto P, Zucconi M, Smirne S. Respiration and heart rate variability during sleep in untreated Parkinson patients. Gerontology 1992;33:92-93.
14. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002;58:1019-1024.
15. Askenasy JJM. Sleep disturbances in Parkinsonism. J Neural Transm 2003;110:125-150.
16. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, and the participants in the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health in collaboration with members of the International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
17. Trenkwalder C, Walters AS, Hening W. Periodic limb movements and restless legs syndrome. Neurol Clin 1996;14:629-650.
18. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-1396.
19. Tan EK, Lum SY, Wong MC. Restless legs syndrome in Parkinson's disease. J Neurol Sci 2002;196:33-36.
20. Happe S, Pirker W, Klösch G, Sauter C, Zeitlhofer J. Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. J Neurol 2003;250:83-86.
21. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001;57:1307-1309.
22. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002;249:164-170.
23. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502-504.
24. 11C-raclopride PET studies. Neurology 1999;52:932-937.
25. Trenkwalder C, Walters AS, Hening WA, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999;14: 141-145.
26. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5:385-391.
27. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):S1-88.
28. Silber MH, Ehrenberg BL, Allen RP, et al., for the Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79: 916-922.
29. Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 2004;24: 249-259.
30. Gagnon J-F, Bédard M-A, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.
31. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622-630.
32. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40-45.
33. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
34. Oksenberg A, Radwan H, Arons E, Hoffenbach D, Behroozi B. Rapid eye movement (REM) sleep behavior disorder: a sleep disturbance affecting mainly older men. Isr J Psychiatry Relat Sci. 2002;39:28-35.
35. Morrison AH. The pathophysiology of REM-sleep behavior disorder. Sleep 1998;21:446-449.
36. Gilman S, Koeppe RA, Chervin RD, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003; 61:29-34.
37. Eisensehr I, von Lindeiner H, Jäger M, Noachtar S. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there a need for polysomnography? J Neurol Sci 2001; 186:7-11.
38. Garcia-Borreguero D, Caminero AB, de la Llave Y, et al. Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness. Mov Disord 2002;17:934-941.
39. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388-393.
40. Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 1996;11:214-216.
41. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.
42. Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001;55:267-269.
43. Dagan Y. Circadian rhythm sleep disorders (CRSD). Sleep Med Rev 2002;6:45-54.
44. Fukuda N, Kobayashi R, Kohsaka M, et al. Effects of bright light at lunchtime on sleep in patients in a geriatric hospital II. Psychiatry Clin Neurosci 2001;55:291-293.
45. Bruguerolle B, Simon N. Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 2002;25:194-201.
46. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of 1-dopa. J Neural Transm Park Dis Dement Sect 1993;5:227-234.
47. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999;14:922-927.
48. Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999;14:507-511.
49. Happe S, Lüdemann P, Berger K, on behalf of the FAQT Study Investigators. The association between disease severity and sleep-related problems in patients with Parkinson's disease. Neuropsychobiology 2002;46:90-96.
50. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1603.
51. Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Curr Psychiatry Rep 2002;4:69-73.
52. Friedman JH, Friedman H. Fatigue in Parkinson's disease: a nine-year follow-up. Mov Disord 2001;16:1120-1122.
53. Abe K, Takanashi M, Yanagihara T. Fatigue in patients with Parkinson's disease. Behav Neurol 2000;12:103-106.
54. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15:986-989.
55. Mayeux R, Chen J, Mirabelle E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40:1513-1517.
56. Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
57. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941.
58. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
59. Hiner BC. Autonomic complications of Parkinson's disease. In: Adler CH, Ahlskog JE, eds. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa, NJ: Humana Press, 2000:161-174.
60. Cummings JL. Managing psychosis in patients with Parkinson's disease. N Engl J Med 1999;340:801-803.
61. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003;18:510-514.
62. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, for the Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-139.
63. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.
64. Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology 2002;59:1979-1981.
65. Cornelia CL. Sleep and Parkinson's disease. In: Adler CH, Ahlskog JE, eds. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa, NJ: Humana Press, 2000:151-160.
66. Arnulf I, Bejjani BP, Garma L, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000;55: 1732-1734.
67. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
68. Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord 2002;17:799-802.
69. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-519.
70. Bennett N, O'Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004;171:749-751.
71. Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995;10:337-340.
72. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994;44:2095-2101.
73. Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology (Berl) 1980;70:163-166.
74. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother 1983; 23:458-464.
75. Zoltoski RK, Velazquez-Moctezuma J, Shiromani PJ, Gillin JC. The relative effects of selective M1 muscarinic antagonists on rapid eye movement sleep. Brain Res 1993;608:186-190.
76. Kales A, Ansel RD, Markham CH, Scharf MB, Tan TL. Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration. Clin Pharmacol Ther 1971;12:397-406.
77. Boivin DB, Montplaisir J. The effects of L-dopa on excessive daytime sleepiness in narcolepsy. Neurology 1991;41:1267-1269.
78. Boivin DB, Montplaisir J, Poirier G. The effects of L-dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 1989;12:339-345.
79. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982;5:183-194.
80. Wyatt RJ, Chase TN, Scott J, Snyder F, Engleman K. Effect of L-dopa on the sleep of man. Nature 1970;228:999-1001.
81. Brunner H, Wetter TC, Hogl B, Yassouridis A, Trenkwalder C, Friess E. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment. Mov Disord 2002;17:928-933.
82. Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson's disease and in their caregivers. Parkinsonism Relat Disord 2004;10:157-168.
83. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, doubleblind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87.
84. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;4:77-80.
85. Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology 2003;60: 1119-1124.
86. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45:1956-1961.
87. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.
88. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
89. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002;324:1483-1487.
90. Homann CN, Wenzel K, Suppan K, Ivanic G, Crevenna R, Ott E. Sleep attacks-facts and fiction: a critical review. Adv Neurol 2003;91:335-341.
91. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
92. Merino-Andreu M, Arnulf I, Konofal E, Derenne JP, Agid Y. Unawareness of naps in Parkinson's disease and in disorders with excessive daytime sleepiness. Neurology 2003;60:1553-1554.
93. Schlesinger I, Ravin PD. Dopamine agonists induce episodes of irresistible daytime sleepiness. Eur Neurol 2003;49:30-33.
94. Ulivelli M, Rossi S, Lombardi C, et al. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 2002;58:462-465.
95. Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson's disease. Neurology 2002;58:1544-1546.
96. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
97. Holloway RG, Shoulson I, Fahn S, et al, for the Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61: 1044-1053.
98. Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18:659-667.
99. Parkes JD, Tarsy D, Marsden CD, et al. Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1975;38: 232-237.
100. Halliday AM, Nathan PW. Methyl phenidate in parkinsonism. BMJ 1961;5240:1652-1655.
101. Solomon P, Mitchell RS, Prinzmetal M. The use of benzedrine sulfate in postencephalitic Parkinson's disease. JAMA 1937;108:1765-1770.
102. Miller E, Nieburg HA. Amphetamines, valuable adjunct in treatment of Parkinsonism. NY State J Med 1973;73:2657-2661.
103. Cornelia CL. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 2003;3:173-180.
104. A receptor antagonists in animal models of Parkinson's disease. Neurology 2003;61(suppl 6):S55-61.
105. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984;34:1092-1094.
106. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001;2:5-17.
107. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909.
108. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000;15:1269-1271.
109. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002;25:111-114.